The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 49-52

  Herrinton, Lisa J ^a   Liu, Liyan ^a   Abramson, Oren ^b   Jaffe, Elaine S ^c  

^a DIVISION OF RESEARCH   (United States)

^b National Cancer Institute ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Autoimmunity; Crohn's disease; Epidemiology; Hepatosplenic T cell lymphoma; HIV AIDS; Incidence

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CHILD; CROHN DISEASE; FEMALE; HEALTH CARE PLANNING; HEPATOSPLENIC T CELL LYMPHOMA; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; MEDICAL HISTORY; MEDICAL RECORD; PERIPHERAL T CELL LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; AGED; CALIFORNIA; COHORT STUDIES; CROHN DISEASE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER NEOPLASMS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; SPLENIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84855351626     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2216     Document Type: Article

References (14)

1. Jaffe E, Harris NL, Stein H, et al. World Health Organization Classification of Tumors/Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2001.
2. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia 2000; 14: 991-997.
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008.
4. Belhadj K, Reyes F, Farcet J-P, et al. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003; 102: 4261-4269.
5. Francois A, Lesesve JF, Stamatoullas A, et al. Hepatosplenic gammadelta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol 1997; 21: 781-790.
6. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-267.
7. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab us in young patients treated for inflammatory bowel disease: Update. J Pediatr Gastroenterol Nutr 2009; 48: 386-8.
8. Thayu M, Markowitz JE, Mamula P, et al. Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005; 40: 220-222.
9. Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003; 44: 531-533.
10. Garwood F. Fiducial Limits for the Poisson Distribution. Biometrica 1936; 28: 437-442.
11. Comparison of Kaiser vs. Non-Kaiser Adults Aged 20-79 in Kaiser Permanente's Northern California Region, 2003. Accessed July 30, 3009.
12. Herrinton LJ. Epidemiology of the Revised European-American Lymphoma (REAL) classification subtypes. Epidemiol Rev, 1998; 20: 189-203.
13. th Congress of the European Hematology Association, June 4-7, 2009. Haematologica 2009; 94[suppl.2]:658 abstract 1720. Accessed July 30, 2009.
14. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P, SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362(15): 1383-95.